Expression of immunological markers on leukemic cells before and after cryopreservation and thawing

Campos, Lydia; Guyotat, Denis; Larese, A.; Archimbaud, E; Mazet, L.; Ehrsam, A.; Fière, D

doi:10.1016/0011-2240(88)90015-6

Cited by 17 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viable AML cells can be stored frozen in liquid nitrogen for an indefinite time, and the viability after cryopreservation is often 80-90% except for the promyelocyte variant, which usually shows less than 10% viability (15). These cells can be used for analysis of membrane molecule phenotype as well as studies of protein expression, chemosensitivity, and regulation of apoptosis (15)(16)(17).…”

Section: Cryopreservation Of Viable Aml Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of Acute Myelogenous Leukemia: Preparation of Samples for Genomic and Proteomic Analyses

Gjertsen

Øyan

Marzolf

et al. 2002

Journal of Hematotherapy & Stem Cell Research

View full text Add to dashboard Cite

During the last decade, several large clinical studies have demonstrated that analysis of chromosomal abnormalities is an essential basis for therapeutic decisions in patients with acute myelogenous leukemia (AML), and cytogenetic studies should now be regarded as mandatory both for routine treatment and as a part of clinical investigations in AML. However, new techniques for detailed genetic characterization and analysis of gene expression as well as protein modulation will become important in the further classification of AML subsets and the development of risk-adapted therapeutic strategies. In this context, we emphasize the importance of population-based clinical studies as a basis for future therapeutic guidelines. Such studies will then require the inclusion of patients at small clinical centers without specialized hematological research laboratories. To document a high and uniform quality of the laboratory investigations, it will be necessary to collect material for later analysis in selected laboratories. In this article, we describe current methods for collection of biological samples that can be used for later preparation of DNA, RNA, and proteins. With the use of gradient-separated AML cells, it should be possible to establish the necessary techniques for collection and handling of biological samples even at smaller centers, and complete collections from all included patients should then be possible even in population-based clinical studies.

show abstract

Section: Cryopreservation Of Viable Aml Cellsmentioning

confidence: 99%

“…These cells can be used for analysis of membrane molecule phenotype as well as studies of protein expression, chemosensitivity, and regulation of apoptosis (15)(16)(17). The use of fresh and cryopreserved AML cells for cytogenetic analysis has also been compared in a small study (18).…”

Section: Cryopreservation Of Viable Aml Cellsmentioning

confidence: 99%

Analysis of Acute Myelogenous Leukemia: Preparation of Samples for Genomic and Proteomic Analyses

Gjertsen

Øyan

Marzolf

et al. 2002

Journal of Hematotherapy & Stem Cell Research

View full text Add to dashboard Cite

show abstract

“…These latter, detrimental effects appear to depend, in part, on the protocols used for cryopreservation and cell storage and, perhaps, on the cell lineage. [205][206][207][208][209][210][211][212][213][214][215][216] Cryopreservation procedures require mononuclear cells be suspended in a solution containing a cryoprotective agent (usually dimethyl sulfoxide), cooled in a cooling device to the storage temperature, and then stored in liquid nitrogen (for use in studies in which viable cells are necessary) or a À808 freezer, which is satisfactory for most molecular studies. Cryopreservation does require specialized equipment and storage facilities, which may not be available in all laboratories.…”

mentioning

confidence: 99%

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology

Arber¹,

Borowitz²,

Cessna³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

100

View full text Add to dashboard Cite

Context.-A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyotype analysis, and often, molecular genetic testing. Although many aspects of the workup for acute leukemia are well accepted, few guidelines have addressed the different aspects of the diagnostic evaluation of samples from patients suspected to have acute leukemia.Objective.-To develop a guideline for treating physicians and pathologists involved in the diagnostic and prognostic evaluation of new acute leukemia samples, including acute lymphoblastic leukemia, acute myeloid leukemia, and acute leukemias of ambiguous lineage.Design.-The College of American Pathologists and the American Society of Hematology convened a panel of experts in hematology and hematopathology to develop recommendations. A systematic evidence review was conducted to address 6 key questions. Recommendations were derived from strength of evidence, feedback received during the public comment period, and expert panel consensus.Results.-Twenty-seven guideline statements were established, which ranged from recommendations on what clinical and laboratory information should be available as part of the diagnostic and prognostic evaluation of acute leukemia samples to what types of testing should be performed routinely, with recommendations on where such testing should be performed and how the results should be reported.Conclusions.-The guideline provides a framework for the multiple steps, including laboratory testing, in the evaluation of acute leukemia samples. Some aspects of the guideline, especially molecular genetic testing in acute leukemia, are rapidly changing with new supportive literature, which will require on-going updates for the guideline to remain relevant.

show abstract

“…How cryopreservation impacts cell cycle fraction measurement by MCM has not been examined (6,(8)(9)(10)(11). Patient sample collection generally necessitates some type of clinical procedure requiring coordination between the clinical care team performing the collection procedure and researchers processing the sample.…”

mentioning

confidence: 99%

“…However, cryopreservation has been noted to have significant effects on protein and gene expression as well as population delineation and even surface marker expression. How cryopreservation impacts cell cycle fraction measurement by MCM has not been examined (6,(8)(9)(10)(11). The goal of this study was to examine the effect of sample storage time and cryopreservation on cell cycle fraction by MCM to determine limits of sample storage time for adequate cell cycle analysis using cultured cells and human samples.…”

mentioning

confidence: 99%

Effect of storage time and temperature on cell cycle analysis by mass cytometry

2018

View full text Add to dashboard Cite

Cell cycle analysis is a recognized and important application of flow cytometry and, more recently, mass cytometry (MCM). Both technologies have been utilized for analysis of the cell cycle state of ex vivo samples from patients with hematologic malignancies. Clinical samples are frequently stored for hours at room temperature or cryogenically frozen before processing and analysis; however, how these processing methods alter cell cycle state is not well described. To understand how storage time and temperature affect the analysis of cell cycle distribution by MCM, two leukemia cell lines, HL-60 and MOLM13, and primary human cells from three human bone marrow aspirates were stored and frozen under a variety of conditions that are likely to be encountered in a clinical setting. Our findings indicate that short delays in sample processing (less than 1 h), have little to no effect on cell cycle distribution, while longer delays or cryopreservation cause significant disruptions to the cell cycle fraction characterized by consistent reductions in IdU incorporation and variable alterations in other cell cycle phases. Analysis of the recovery of cryopreserved leukemia cell lines and marrow cells demonstrated that cell cycle alterations persist for at least 48 h after thawing. Our findings demonstrate that accurate cell cycle analysis requires that samples be processed rapidly after collection, and that cryopreservation significantly alters cell cycle fractions. Measurement of IdU incorporation was the most sensitive to both delays in processing and cryopreservation, while estimation of the total cycling cell fraction using Ki-67 or phosphorylated retinoblastoma protein were least altered by the conditions tested. These findings provide guidance for the ideal approach to collection of samples for cell cycle analysis and can aid interpretation of cell cycle data from samples that cannot be collected under ideal circumstances.

show abstract

Expression of immunological markers on leukemic cells before and after cryopreservation and thawing

Cited by 17 publications

References 17 publications

Analysis of Acute Myelogenous Leukemia: Preparation of Samples for Genomic and Proteomic Analyses

Analysis of Acute Myelogenous Leukemia: Preparation of Samples for Genomic and Proteomic Analyses

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology

Effect of storage time and temperature on cell cycle analysis by mass cytometry

Contact Info

Product

Resources

About